Atreca Inc at Cowen IO Next Summit (Virtual) Transcript
Good afternoon, and welcome once again to Cowen & Company's IO Next Summit. I'm Phil Nadeau, a biotech analyst here at Cowen, and it's my pleasure to moderate the next session with Atreca. We have from Atreca John Orwin, Tito Serafini, Steven Gould, and Alex Gray.
We'll jump right into the questions and maybe start with the discussion of ATRC-101, maybe just a brief background. Tito, for those less familiar, you could give a brief introduction to 101, summarize this preclinical data, and its mechanism of action.
Sure. Thanks, Phil, for having us here today to chat about Atreca. So the 101 is our most advanced program. The target is a ribonucleoprotein complex that's tumor specific 101 and came from our platform. This complex was discovered by virtue of our discovering the antibody we engineered into 101.
It's mechanism of action involves binding to this ribonucleoprotein complex and then delivering that complex to the innate immune system cells present
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |